Omthera Pharmaceuticals, Inc. to Present at Leerink Swann 2012 Global Healthcare Conference and Citi 2012 Global Healthcare Conference
PRINCETON, N.J., Feb. 15, 2012 /PRNewswire/ -- Omthera Pharmaceuticals, Inc., a privately held emerging specialty pharmaceuticals company, announced today that Jerry Wisler, President and Chief Executive Officer, will present at the Leerink Swann 2012 Global Healthcare Conference on Thursday, February 16, 2012 at 3:20 p.m. EST. He will also present at the Citi Global Healthcare Conference on February 29, 2012 at 11:00 a.m. EST. Both conferences will be held at the Waldorf Astoria Hotel, New York, NY.
About Omthera Pharmaceuticals, Inc.
Founded in 2008, Omthera Pharmaceuticals, Inc. is a privately held, emerging specialty pharmaceutical company focusing its efforts on the clinical development of new therapies for dyslipidemia. Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease. In March 2011, the Company initiated a pivotal Phase III clinical trial for its lead product candidate, Epanova™, an Omega-3 fatty acid compound in development as a triglyceride-lowering adjunct therapy to diet in patients with very high triglycerides (greater than or equal to 500 mg/dL). In August 2011, Omthera initiated a Phase III trial for Epanova in patients with high triglycerides (greater than or equal to 200 mg/dL and less than or equal to 500 mg/dL) currently on statin therapy. Omthera holds worldwide rights to Epanova under a license from Chrysalis Pharma AG, a privately held Swiss company. For more information, please visit www.omthera.com.
Chief Financial Officer
Omthera Media Relations:
Vice President Public Relations
Rx Communications Group, LLC
SOURCE Omthera Pharmaceuticals, Inc.
More by this Source
Omthera Stockholders Approve Acquisition by AstraZeneca
Jul 16, 2013, 12:00 ET
Omthera Announces Waiver of Lock-Up Restriction
Jul 11, 2013, 09:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.